Quarterly report pursuant to Section 13 or 15(d)

7. Stockholders' Equity (Details Narrative)

v3.8.0.1
7. Stockholders' Equity (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
In process research and development expense $ 0 $ 0 $ 0 $ 39,500,000  
Debt and Equity Financing [Member]          
Warrants outstanding 3,522,225   3,522,225   3,522,225
Warrants weighted average exercise price $ 4.30   $ 4.30    
Pharmsynthez [Member]          
Debt converted, shares issued     125,397    
Stock issued for asset purchase, shares         3,378,788
In process research and development expense         $ 39,500,000
Serum [Member]          
Stock issued in exchange for product, shares         211,486
Stock issued in exchange for product, value         $ 800,000
Series B Preferred Stock [Member]          
Conversion of stock, shares converted     185,000    
Common Stock [Member]          
Conversion of stock, shares issued     185,000    
Common Stock [Member] | SynBio [Member]          
Conversion of stock, shares converted         970,000
Series A Preferred Stock [Member] | SynBio [Member]          
Conversion of stock, shares issued         970,000